29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

Key Takeaways Explain This Topic AI

Accurate diagnosis of Acute Otitis Media (AOM) under AAP guidelines requires moderate-to-severe tympanic membrane (TM) bulging, new-onset otorrhea not from otitis externa, or mild TM bulging with acute-onset (<48 hours) otalgia or intense erythema; isolated TM erythema without bulging or reduced mobility does NOT constitute AOM.

High-dose amoxicillin (80 to 90 mg/kg/day divided BID) is the first-line antibiotic for pediatric AOM to achieve middle-ear concentrations that overcome penicillin-intermediate Streptococcus pneumoniae; high-dose amoxicillin-clavulanate (90 mg/kg/day amoxicillin with 6.4 mg/kg/day clavulanate in a 14:1 ratio) is indicated if amoxicillin was used within 30 days, if concurrent purulent conjunctivitis is present (otitis-conjunctivitis syndrome), or if symptoms fail to improve after 48-72 hours.

Watchful waiting with observation for 48 to 72 hours without initial antibiotics is permissible ONLY for non-severe unilateral AOM in children aged 6 to 23 months, or non-severe unilateral/bilateral AOM in children >=24 months; immediate antibiotics are mandatory for infants <6 months, children 6 to 23 months with bilateral AOM, and any child presenting with severe illness (fever >=39°C or severe otalgia).

Otitis Media with Effusion (OME) is middle ear fluid without acute infection (amber or dull retracted TM, decreased pneumatic mobility); antibiotics, oral decongestants, and antihistamines are strictly contraindicated; 90% resolve spontaneously within 3 months, and tympanostomy tube placement is reserved for persistent bilateral effusion >=3 months with documented hearing loss or developmental delay.

Acute Otitis Externa is treated with topical ciprofloxacin-dexamethasone (neomycin drops contraindicated with TM perforation); malignant otitis externa is Pseudomonas skull base osteomyelitis in elderly diabetics with severe nocturnal otalgia, granulation tissue, and CN VII palsy, requiring emergent CT and prolonged IV antipseudomonals.

Last updated: September 2026

Acute Otitis Media (AOM): Pathogenesis & Microbiologic Landscape

Acute Otitis Media (AOM) is defined as an acute, suppurative bacterial or viral infection of the middle ear fluid cavity. It represents the single most common reason for antibiotic administration in pediatric patients in North America, with peak incidence occurring between 6 and 24 months of age .

Anatomic Predisposition & Pathophysiologic Cascade

The profound vulnerability of infants and young children to middle ear disease stems directly from the developmental anatomy of the Eustachian tube :

In infants, the Eustachian tube is shorter (approximately 18 mm vs. 36 mm in adults), wider, more compliant, and oriented horizontally at an angle of only 10 degrees relative to the horizontal plane (compared to 45 degrees in adults).

The tensor veli palatini muscle, which actively dilates the tube during swallowing and yawning, has an inefficient biomechanical pull in infancy. PATHOPHYSIOLOGY OF ACUTE OTITIS MEDIA

• Viral URI / Allergic Rhinitis
• │
• ▼
• Nasopharyngeal & Tubal Mucosal Edema
• │
• ▼
• Functional Eustachian Tube Dysfunction
• │
• ▼
• Negative Middle Ear Intracavitary Pressure
• │
• ▼
• Aspiration of Colonized Nasopharyngeal Flora
• (S. pneumoniae, H. influenzae, M. catarrhalis)
• │
• ▼
• Suppuration & Middle Ear Effusion (MEE)
• │
• ▼
• TM Bulging, Intense Erythema & Otalgia
• Microbiologic Spectrum

Streptococcus pneumoniae (~30% to 35%): Historically responsible for up to 50% of cases prior to 7-, 13-, 15-, and 20-valent pneumococcal conjugate vaccines. It is associated with the highest fevers, most severe otalgia, and greatest risk of acute mastoiditis and tympanic membrane perforation. Penicillin resistance is mediated by altered penicillin-binding proteins (PBPs) rather than beta-lactamase production.

Haemophilus influenzae (non-typeable) (~35% to 40%): Now rivals or exceeds S. pneumoniae as the most prevalent bacterial pathogen in post-conjugate vaccine populations. Approximately 30% to 40% of strains produce beta-lactamase , rendering them resistant to standard amoxicillin. Frequently associated with concurrent purulent conjunctivitis ( otitis-conjunctivitis syndrome ).

Moraxella catarrhalis (~10% to 15%): Greater than 90% to 95% of isolates produce beta-lactamase . Characterized by higher spontaneous bacteriologic clearance rates (~75%) and milder clinical presentations.

Viral Pathogens : Respiratory syncytial virus (RSV), rhinoviruses, influenza, coronaviruses, and adenoviruses are co-isolated in 40% to 70% of middle ear aspirates, explaining why 10% to 15% of children fail to improve despite culture-appropriate antibiotic therapy.

AAP Diagnostic Criteria & Physical Examination Pearls

Overdiagnosis of AOM has historically driven rampant pediatric antibiotic overuse. In response, the American Academy of Pediatrics (AAP) and the American Academy of Family Physicians (AAFP) established strict, evidence-based diagnostic criteria requiring objective confirmation of acute suppuration and middle ear effusion (MEE): AAP / AAFP DIAGNOSTIC CRITERIA FOR AOM

A diagnosis of Acute Otitis Media REQUIRES either Criterion 1 OR Criterion 2:

• ┌─────────────────────────────────────────────────────────────────────────┐
• │ CRITERION 1: │
• │ • Moderate to severe BULGING of the tympanic membrane (TM) │
• │ OR │
• │ • New onset otorrhea NOT attributable to acute otitis externa │
• ├─────────────────────────────────────────────────────────────────────────┤
• │ CRITERION 2: │
• │ • Mild bulging of the TM accompanied by: │
• │ - Recent onset (<48 hours) of ear pain (holding/tugging ear in child)│
• │ OR │
• │ - Intense erythema of the tympanic membrane │
• └─────────────────────────────────────────────────────────────────────────┘

CRITICAL RULE: NEVER diagnose AOM based solely on TM redness without bulging!

Examination Pearls: The Bulging Membrane

Moderate-to-Severe TM Bulging : Represents the single most reliable, sensitive, and specific physical examination sign of acute suppuration (positive likelihood ratio [LR+] of 40 to 50). The normal translucent, concave membrane becomes convex, with the malleus handle and umbo obscured or retracted into the edematous tissue, often displaying a 'donut' or 'bagel' configuration.

Pneumatic Otoscopy (The Gold Standard) : Examination of the tympanic membrane without pneumatic assessment is incomplete. Applying gentle positive and negative pressure via an airtight pneumatic bulb evaluates TM mobility. In the presence of middle ear fluid, membrane mobility is severely diminished or entirely absent .

The Diagnostic Pitfall of Erythema : A crying infant, high fever, vigorous coughing, or removal of impacted cerumen naturally triggers marked capillary dilatation and blushing of the tympanic membrane. A red TM without bulging or decreased mobility is NOT acute otitis media and must never be treated with antibiotics!

Initial Management: Immediate Antibiotics vs. Watchful Waiting

The AAP guidelines emphasize a stratified management paradigm that distinguishes children who mandate immediate antimicrobial therapy from those who are candidates for watchful waiting (observation) : AOM MANAGEMENT STRATIFICATION: ANTIBIOTICS vs. OBSERVATION

• AGE GROUP UNILATERAL / BILATERAL RECOMMENDED ACTION
• ─────────────────────────────────────────────────────────────────────────
• <6 Months Any presentation IMMEDIATE ANTIBIOTICS
• (Severe or non-severe) (Always treat immediately)
• ─────────────────────────────────────────────────────────────────────────
• 6 to 23 Months Severe Illness* IMMEDIATE ANTIBIOTICS
• (Unilateral or Bilateral) (High-dose Amoxicillin)
• ──────────────────────────────────────────────────────
• Bilateral Non-Severe IMMEDIATE ANTIBIOTICS
• ──────────────────────────────────────────────────────
• Unilateral Non-Severe WATCHFUL WAITING OPTION
• (Observe 48-72h with analgesia
• OR immediate antibiotics)
• ─────────────────────────────────────────────────────────────────────────
• >=24 Months Severe Illness* IMMEDIATE ANTIBIOTICS
• ──────────────────────────────────────────────────────
• Non-Severe WATCHFUL WAITING OPTION
• (Unilateral or Bilateral) (Observe 48-72h with analgesia
• OR immediate antibiotics)
• ─────────────────────────────────────────────────────────────────────────
• *Severe Illness: Moderate-to-severe otalgia, otalgia persisting >=48 hours,

or core body temperature >=39.0°C (102.2°F).

The Watchful Waiting Protocol

Eligibility : Permissible only when reliable parents/caregivers agree to close observation, pain management is initiated immediately, and a definitive mechanism is established for reassessment within 48 to 72 hours .

Implementation : The clinician provides symptomatic treatment with weight-based oral analgesics (ibuprofen or acetaminophen) and either schedules a 48-hour clinic follow-up or dispenses a safety-net / delayed prescription with explicit instructions to fill it only if symptoms worsen or fail to show clear improvement after 48 to 72 hours.

Evidence : Approximately 65% to 70% of children with non-severe AOM achieve complete resolution without antibiotics , avoiding drug-induced adverse events (gastrointestinal upset, diarrhea, diaper candidiasis) and sparing selective microbial resistance.

Evidence-Based Antimicrobial Regimens & Formulation Pharmacokinetics

When antimicrobial therapy is initiated for pediatric AOM, dosing and agent selection must overcome intermediate-level pneumococcal resistance and cover beta-lactamase-producing organisms.

First-Line Regimen: High-Dose Amoxicillin

Dosing : Amoxicillin 80 to 90 mg/kg/day PO divided into 2 doses (BID) .

Pharmacokinetic Rationale : Traditional standard-dose amoxicillin (40 to 45 mg/kg/day) achieves middle ear fluid concentrations of 1 to 2 mcg/mL, which is sufficient for fully susceptible S. pneumoniae (MIC <=0.06 mcg/mL), but completely fails against penicillin-intermediate strains (MIC 1 to 2 mcg/mL). In contrast, high-dose amoxicillin (80 to 90 mg/kg/day) achieves middle ear fluid levels exceeding 6 to 8 mcg/mL , saturating altered penicillin-binding proteins (PBPs) and reliably eradicating intermediate-resistant pneumococci.

Duration of Therapy :

• Children <2 years of age or any child with severe illness: 10 days ;
• Children 2 to 5 years of age with mild-to-moderate illness: 7 days ;

Children >=6 years of age with mild-to-moderate illness: 5 to 7 days .

High-Dose Amoxicillin-Clavulanate: When & Why

Indications for High-Dose Augmentin as First-Line :

Prior Amoxicillin Exposure : Child received amoxicillin within the preceding 30 days (selects for beta-lactamase-producing H. influenzae and M. catarrhalis );

Otitis-Conjunctivitis Syndrome : Concurrent purulent conjunctivitis and AOM (indicates non-typeable H. influenzae in >70% of cases);

Treatment Failure : Lack of clinical improvement after 48 to 72 hours of first-line high-dose amoxicillin;

History of Recurrent AOM : Documented failures on amoxicillin alone.

The 14:1 Ratio Pharmacokinetic Rule : Standard amoxicillin-clavulanate suspensions contain a 4:1 or 7:1 ratio of amoxicillin to clavulanate. At high doses (90 mg/kg/day), standard formulations supply excessive amounts of clavulanate, which directly stimulates gastrointestinal motility receptors, triggering profuse secretory diarrhea. Therefore, clinicians must prescribe the 14:1 formulation (Augmentin ES-600) , which supplies 90 mg/kg/day of amoxicillin with only 6.4 mg/kg/day of clavulanate , maximizing bacterial eradication while drastically minimizing diarrhea. PEDIATRIC AOM ANTIMICROBIAL DOSING SUMMARY

• FIRST-LINE THERAPY (No Prior Abx in 30 Days; No Conjunctivitis)
• High-Dose Amoxicillin: 80 to 90 mg/kg/day PO divided BID

FIRST-LINE WITH BETA-LACTAMASE COVERAGE (Prior Abx <30d OR Conjunctivitis)

• High-Dose Amoxicillin-Clavulanate (Augmentin ES-600, 14:1 ratio):

90 mg/kg/day amoxicillin + 6.4 mg/kg/day clavulanate divided BID

• PENICILLIN ALLERGY: NON-TYPE I (Non-Anaphylactic Cutaneous Rash)
• Cefdinir: 14 mg/kg/day PO once daily or divided BID
• Cefuroxime axetil: 30 mg/kg/day PO divided BID
• Cefpodoxime: 10 mg/kg/day PO divided BID

• PENICILLIN ALLERGY: SEVERE TYPE I (Anaphylaxis, Angioedema, Urticaria)
• Azithromycin: 10 mg/kg on Day 1, then 5 mg/kg Days 2-5
• Clarithromycin: 15 mg/kg/day PO divided BID

• CLINICAL FAILURE AT 48-72 HOURS OR PERSISTENT VOMITING
• Intramuscular Ceftriaxone: 50 mg/kg IM once daily for 1 to 3 days
• Otitis Media with Effusion (OME / Serous Otitis): Assessment & Guideline Recommendations
• Definition & Pathophysiology

Otitis Media with Effusion (OME), commonly termed serous otitis media , is defined as fluid in the middle ear cavity without symptoms or signs of acute ear infection (absence of otalgia, fever, TM bulging, or acute inflammatory erythema).

Natural History : OME develops following more than 90% of resolved AOM episodes . Approximately 70% of children demonstrate persistent middle ear effusion at 2 weeks post-AOM, 40% at 1 month, and 10% to 15% at 3 months.

Physical Examination Findings : Pneumatic otoscopy reveals an intact, non-bulging, translucent, gray or amber-colored tympanic membrane that is frequently retracted (prominent lateral process of the malleus with foreshortened handle). Visible air-fluid levels or fluid meniscus bubbles behind the TM are pathognomonic. Pneumatic testing demonstrates markedly decreased or absent mobility . Tympanometry confirms a Type B (flat) tracing. DIAGNOSTIC CONTRAST: AOM vs. OME vs. AOE vs. NOE

• FEATURE AOM OME AOE NOE
• ─────────────────────────────────────────────────────────────────────────
• Location Middle Ear Middle Ear External Canal Skull Base
• Pain / Otalgia Severe, acute NONE Severe on tragus Severe, deep,
• (fullness only) or pinna motion nocturnal
• Systemic Fever Common (>=38°C) ABSENT Absent Variable
• TM Appearance BULGING, red, RETRACTED, Normal or Normal or
• opaque amber, bubbles obscured granulation
• Canal Wall Normal Normal Erythematous, Granulation at
• edematous, pus bony-cart jct
• First-Line Tx Oral High-Dose WATCHFUL Topical Cipro- IV Cefepime/Cipro
• Amoxicillin WAITING (3 mo) Dexamethasone x 6-8 weeks
• Clinical Practice Guidelines for OME (AAO-HNS / AAP)

Extensive randomized controlled clinical trials have conclusively evaluated pharmacotherapy for uncomplicated OME:

STRONG RECOMMENDATION AGAINST : Oral antibiotics, systemic antihistamines, oral/nasal decongestants, and systemic or intranasal corticosteroids are completely ineffective in accelerating long-term fluid clearance. They expose young children to drug toxicity and must NOT be prescribed.

Evidence-Based Watchful Waiting : The clinician should manage uncomplicated OME with watchful waiting, re-evaluating the child at 3-month intervals until the effusion resolves (spontaneous resolution occurs in >75% to 90% by 3 months).

Indications for Tympanostomy Tube Placement

Surgical intervention is indicated when persistent middle ear effusion causes functional impairment or anatomical destruction:

Bilateral OME persisting for >=3 months accompanied by documented bilateral hearing loss (bilateral conductive hearing threshold loss >=20 to 30 dB confirmed on formal audiometry);

Unilateral or bilateral OME persisting >=3 months in a child with speech or language developmental delay, autism spectrum disorder, Down syndrome, or craniofacial abnormalities (cleft palate);

Structural damage to the tympanic membrane, including deep retraction pockets, adhesive otitis ('glue ear'), or ossicular erosion.

Surgical Procedure : Bilateral myringotomy with insertion of tympanostomy tubes (grommets) . Tubes ventilate the middle ear, bypass the Eustachian tube, equalize pressure, and immediately restore conductive hearing. Concurrent adenoidectomy is recommended if the child is >=4 years of age or has chronic nasal obstruction/adenoiditis.

Loading diagram... Triage and Management of Middle and External Ear Pathologies